Costs of irritable bowel syndrome in the UK and US

  title={Costs of irritable bowel syndrome in the UK and US},
  author={Stefanie Maxion-Bergemann and Frank Thielecke and Florian Abel and Rito Bergemann},
Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders, with an estimated prevalence rate in the general population of 10–15% in industrialised countries. Although IBS is not a life-threatening disease, it contributes significantly to a large segment of healthcare resource consumption. This review provides an overview of studies addressing the direct and indirect costs of IBS in the US and the UK. A systematic literature search was conducted in MEDLINE… 

Irritable bowel syndrome.

This systematic review presents information relating to the effectiveness and safety of the following interventions: 5HT(3) receptor antagonists (alosetron and ramosetron);5HT(4) receptor agonists (tegaserod); antidepressants (tricyclic antidepressants and selective serotonin reuptake inhibitors]; antispasmodics (including peppermint oil); cognitive behavioural therapy (CBT); hypnotherapy; soluble and insoluble fibre supplementation; and loperamide.

Societal costs for irritable bowel syndrome – a population based study

The more restrictive Rome II criteria identify an IBS population incurring higher GI related individual costs than Manning criteria, suggesting that guideline recommendations for avoiding repeated diagnostic procedures may not be followed.

Irritable bowel syndrome with constipation: a European-focused systematic literature review of disease burden

There is a clear need for European-focused IBS-C burden- of-disease and cost-of-illness studies to address identified evidence gaps, and there is a need for new therapies for Ibs-C that are effective, well tolerated, and have a positive impact on HRQoL.

Burden of irritable bowel syndrome in an increasingly cost-aware National Health Service

Better diagnosing, through improved clinical coding and standardisation of diagnostic criteria, is required to more accurately assess the true burden of Irritable bowel syndrome and allow optimal management of IBS.

Burden of constipation-predominant irritable bowel syndrome (IBS-C) in France, Italy, and the United Kingdom

Findings highlight the pervasive influence of IBS-C on the day-to-day functioning of sufferers, their ability to be productive at work, and their influence on the wider health care system.

Economic burden of irritable bowel syndrome in China

IBS-M patients appear to have the greatest economic burden but require further confirmation, and more than two-thirds of total annual costs of IBS consist of inpatient and outpatient healthcare use.

IBS clinical management in Italy: The AIGO survey.

  • M. SonciniC. Stasi A. Balzano
  • Medicine
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2019

5-Aminosalicylic acid for treatment of irritable bowel syndrome

This first meta-analysis focusing on mesalazine for the treatment of IBS is predicted to provide high-quality synthesis on existing evidence for IBS and a relatively comprehensive reference for clinical practice and development of clinical guidelines for Ibs.

Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis.

  • R. M. LovellA. Ford
  • Medicine
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2012



Resource Utilization Associated with Irritable Bowel Syndrome in the United States: 1987–1997

The study found an apparent decreasing trend of IBS-related hospitalizations and no marked increase in office consultations in the past decade and a better case identification criterion is necessary to estimate the true disease burden.

The epidemiology of irritable bowel syndrome in North America: a systematic review

Approximately 30 million people in North America meet the diagnostic criteria for IBS, however, data about the natural history of IBS is quite sparse and renewed efforts should be focused at developing appropriately designed trials of the epidemiology of Ibs.

Impact of Irritable Bowel Syndrome on Quality of Life and Resource Use in the United States and United Kingdom

IBS has a significant impact on quality of life and resource use in both the US and UK, and appears to be greater in the UK than in the US, while the general health status of persons with IBS in either country was much poorer.

Economic Burden of Irritable Bowel Syndrome

AbstractIt has been suggested that the annual direct costs for irritable bowel syndrome (IBS) are now around $US41 billion in the 8 most industrialised countries. This paper reviews the data on

The economic burden of irritable bowel syndrome in Canada.

The present study examines a set of patients who have been diagnosed with IBS and seek medical care for IBS, and examines the direct and indirect costs incurred in the course of treatment forIBS, excluding the costs of unrelated medical conditions.

The Economic Impact of Irritable Bowel Syndrome in a Managed Care Setting

Patients with an IBS diagnosis represent a substantial cost to managed care before and after the diagnosis of IBS and further research is warranted to identify these patients earlier, and to prevent the economic burden associated with them.

Irritable bowel syndrome: definition, diagnosis and epidemiology.

  • N. Talley
  • Medicine
    Bailliere's best practice & research. Clinical gastroenterology
  • 1999
The development of acceptable, symptom-based diagnostic criteria has advanced the field, stimulating interest in the pathophysiology and targeted pharmacological therapy, which are essential steps if the disease burden is to be reduced.

Irritable Bowel Syndrome, Health Care Use, and Costs: A U.S. Managed Care Perspective

It is found that IBS is associated with a broad pattern of increased health care use and costs and the severity of abdominal pain/discomfort is a significant predictor of health careUse and costs for patients with IBS compared with non-IBS subjects.

Costs of care for irritable bowel syndrome patients in a health maintenance organization

Patients with IBS show sustained increases in health care costs relative to population controls for both lower GI services and care unrelated to lower GI problems, however, the majority of the excess resulted from medical care not directly related to lowerGI problems.